

# **C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Pipeline Review, H2 2017**

<https://marketpublishers.com/r/C2A32A17757EN.html>

Date: August 2017

Pages: 100

Price: US\$ 3,500.00 (Single User License)

ID: C2A32A17757EN

## **Abstracts**

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H2 2017

## **SUMMARY**

According to the recently published report 'C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2017'; C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) pipeline Target constitutes close to 26 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by

increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extracellular ubiquitin, leading to enhanced intracellular calcium ions and reduced cellular cAMP levels. It is involved in hematopoiesis and in cardiac ventricular septum formation. It also plays an essential role in vascularization of the gastrointestinal tract, probably by regulating vascular branching and/or remodeling processes in endothelial cells.

The report 'C-X-C Chemokine Receptor Type 4 - Pipeline Review, H2 2017' outlays comprehensive information on the C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 8 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Cardiovascular, Immunology, Respiratory, Gastrointestinal, Genetic Disorders, Hematological Disorders, Ophthalmology and Women's Health which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Human Immunodeficiency Virus (HIV) Infections (AIDS), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Breast Cancer, Colon Cancer, Melanoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Small-Cell Lung Cancer, Solid Tumor, Uveal Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Allergic Asthma, Aplastic Anemia, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Glioblastoma Multiforme (GBM), Hematopoietic Stem Cell Transplantation, Idiopathic Pulmonary Fibrosis, Inflammation, Intimal Hyperplasia, Liver Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myocardial Infarction, Neuroblastoma, Non-Alcoholic Steatohepatitis (NASH), Pancreatic Ductal

Adenocarcinoma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Thrombocytopenia, Vasomotor Symptoms of Menopause (Hot Flashes), Waldenstrom Macroglobulinemia, Wet (Neovascular/Exudative) Macular Degeneration, WHIM Syndrome (Warts, Hypogammaglobulinemia and Infections and Myelokathexis).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

The report reviews C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects

The report assesses C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor

or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte

Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Overview

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Companies Involved in Therapeutics Development

AdAlta Ltd

Ambrx Inc

BioLineRx Ltd

Bristol-Myers Squibb Company

Eli Lilly and Company

Globavir Biosciences Inc

GlycoMimetics Inc

Pfizer Inc

Pharis Biotec GmbH

Polyphor Ltd

TaiGen Biotechnology Co Ltd

Upsher-Smith Laboratories Inc

X4 Pharmaceuticals Inc

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Drug Profiles

AD-114 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALB-408 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-3114 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

balixafortide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BL-8040 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

burixafor – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GBV-4086 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMI-1359 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HPH-112 – Drug Profile



Product Description  
Mechanism Of Action  
R&D Progress  
HPH-196 – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
HPH-211 – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
hz-515H7 – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
LY-2510924 – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
PF-06747143 – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
POL-5551 – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Protein to Agonize CXCR4 for Inflammation – Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress



PTX-9908 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-122 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Antagonize CXCR4 for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Target CXCR4 and SDF-1 for HIV – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ulocuplumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

USL-311 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-4P001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-4P002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Dormant Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) –

*C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain...*

## Discontinued Products

C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Product Development Milestones

## Featured News & Press Releases

Jul 18, 2017: AD-114 safe in non-human primates and manufacturing progress update

Jul 10, 2017: BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration

Jun 01, 2017: BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors

May 25, 2017: X4 Pharmaceuticals Announces Initiation of the Phase 2 Expansion of its Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma

May 22, 2017: BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML

May 08, 2017: AdAlta to present eye fibrosis data at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA

Mar 21, 2017: AdAlta expands collaboration with The Alfred Hospital

Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment

Mar 02, 2017: GlycoMimetics to Present New Preclinical Data of GMI-1359 at AACR Annual Meeting 2017

Jan 30, 2017: X4 Pharmaceuticals Announces Initiation of a Phase 2/3 Clinical Study of X4P-001-LD in Patients with WHIM Syndrome, a Rare Genetic Primary Immunodeficiency Disease

Jan 26, 2017: X4 Pharmaceuticals Announces Initiation of Clinical Study of X4P-001 in Combination with Opdivo for Patients with Advanced Clear Cell Renal Cell

Jan 18, 2017: AdAlta receives Orphan Designation for its lead drug candidate targeting patients with idiopathic pulmonary disease

Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer

Jan 09, 2017: AdAlta Announces Positive Pre-clinical Data Showing Lead Drug Candidate Has Broad Fibrosis Treatment Potential

## Appendix

## Methodology

## Coverage

[Secondary Research](#)  
[Primary Research](#)  
[Expert Panel Validation](#)  
[Contact Us](#)  
[Disclaimer](#)

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2017  
Number of Products under Development by Therapy Areas, H2 2017  
Number of Products under Development by Indications, H2 2017  
Number of Products under Development by Indications, H2 2017 (Contd.1), H2 2017  
Number of Products under Development by Indications, H2 2017 (Contd.2), H2 2017  
Number of Products under Development by Companies, H2 2017  
Products under Development by Companies, H2 2017  
Products under Development by Companies, H2 2017 (Contd.1), H2 2017  
Products under Development by Companies, H2 2017 (Contd.2), H2 2017  
Products under Development by Companies, H2 2017 (Contd.3), H2 2017  
Number of Products under Investigation by Universities/Institutes, H2 2017  
Products under Investigation by Universities/Institutes, H2 2017  
Number of Products by Stage and Mechanism of Actions, H2 2017  
Number of Products by Stage and Route of Administration, H2 2017  
Number of Products by Stage and Molecule Type, H2 2017  
Pipeline by AdAlta Ltd, H2 2017  
Pipeline by Ambrx Inc, H2 2017  
Pipeline by BioLineRx Ltd, H2 2017  
Pipeline by Bristol-Myers Squibb Company, H2 2017  
Pipeline by Eli Lilly and Company, H2 2017  
Pipeline by Globavir Biosciences Inc, H2 2017  
Pipeline by GlycoMimetics Inc, H2 2017  
Pipeline by Pfizer Inc, H2 2017  
Pipeline by Pharis Biotec GmbH, H2 2017  
Pipeline by Polyphor Ltd, H2 2017  
Pipeline by TaiGen Biotechnology Co Ltd, H2 2017  
Pipeline by Upsher-Smith Laboratories Inc, H2 2017  
Pipeline by X4 Pharmaceuticals Inc, H2 2017  
Dormant Products, H2 2017  
Dormant Products, H2 2017 (Contd.1), H2 2017  
Dormant Products, H2 2017 (Contd.2), H2 2017  
Dormant Products, H2 2017 (Contd.3), H2 2017  
Discontinued Products, H2 2017

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

### COMPANIES MENTIONED

AdAlta Ltd

Ambrx Inc

BioLineRx Ltd

Bristol-Myers Squibb Company

Eli Lilly and Company

Globavir Biosciences Inc

GlycoMimetics Inc

Pfizer Inc

Pharis Biotec GmbH

Polyphor Ltd

TaiGen Biotechnology Co Ltd

Upsher-Smith Laboratories Inc

X4 Pharmaceuticals Inc

## I would like to order

Product name: C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) – Pipeline Review, H2 2017

Product link: <https://marketpublishers.com/r/C2A32A17757EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C2A32A17757EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970